MENU
+Compare
INZY
Stock ticker: NASDAQ
AS OF
Apr 2 closing price
Price
$0.93
Change
+$0.06 (+6.90%)
Capitalization
59.51M

INZY Inozyme Pharma Forecast, Technical & Fundamental Analysis

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function... Show more

INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for INZY with price predictions
Apr 02, 2025

INZY's Stochastic Oscillator remains in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INZY's RSI Indicator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INZY advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

INZY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INZY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INZY entered a downward trend on March 31, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.029) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.036).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INZY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INZY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INZY is expected to report earnings to fall 2.78% to -39 cents per share on May 13

Inozyme Pharma INZY Stock Earnings Reports
Q1'25
Est.
$-0.40
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.05
Q2'24
Missed
by $0.04
Q1'24
Missed
by $0.03
The last earnings report on March 10 showed earnings per share of -40 cents, missing the estimate of -40 cents. With 379.48K shares outstanding, the current market capitalization sits at 59.51M.
A.I. Advisor
published General Information

General Information

a company, which engages in the research and development of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
321 Summer Street
Phone
+1 857 330-4340
Employees
59
Web
https://www.inozyme.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TBI5.640.33
+6.21%
Trueblue
USLM92.991.74
+1.91%
United States Lime & Minerals
BLK961.8417.76
+1.88%
Blackrock
AGNC9.48-0.01
-0.11%
AGNC Investment Corp
MATH1.88-0.03
-1.57%
Metalpha Technology Holding Limited

INZY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INZY has been loosely correlated with IGMS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INZY jumps, then IGMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INZY
1D Price
Change %
INZY100%
+6.48%
IGMS - INZY
53%
Loosely correlated
+6.96%
MRSN - INZY
50%
Loosely correlated
+1.68%
CRNX - INZY
48%
Loosely correlated
+2.51%
DYN - INZY
48%
Loosely correlated
+7.37%
APGE - INZY
46%
Loosely correlated
+6.23%
More